PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Transaction in Own Shares

10 Feb 2016 17:18

RNS Number : 7139O
Reckitt Benckiser Group PLC
10 February 2016
 

RECKITT BENCKISER GROUP PLC

 

TRANSACTION IN OWN SECURITIES

 

 

 

Reckitt Benckiser Group plc ("RB") announces today that it has purchased the following number of its ordinary shares of 10p each (the "Ordinary Shares") on the London Stock Exchange from Morgan Stanley & Co. International PLC ("Morgan Stanley"). Such purchase was effected pursuant to irrevocable instructions issued by RB on 30 December 2015, as announced on 30 December 2015:

 

Ordinary Shares

 

Date of purchase:

10 February 2016

Number of Ordinary Shares purchased:

180,754

Price per share:

£59.8363

 

RB intends to hold the purchased shares in treasury.

 

Following the above transaction, RB holds 30,044,285 Ordinary Shares in treasury and has 706,490,894 Ordinary Shares in issue (excluding treasury shares).

 

These purchases are the last purchases to be made under the irrevocable programme between RB, on the one hand, and Morgan Stanley, on the other hand, announced on 30 December 2015, as that irrevocable programme has been completed in accordance with its terms.

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

Contact:

Christine Logan

Company Secretary

Reckitt Benckiser Group plc

01753 217800

 

 

 

About RB:

 

RB* is the world's leading consumer health and hygiene company. The company has operations in over 60 countries, with headquarters in London, Dubai and Amsterdam, and sales in most countries across the globe. The company employs approximately c. 37,000 people worldwide.

 

Inspired by a purpose to deliver innovative solutions for healthier lives and happier homes, RB is in the top 20 companies listed on the London Stock Exchange. We are the global No 1 or No 2 in the majority of our fast-growing categories, driven by an exceptional focus on innovation. Our health, hygiene and home portfolio is led by our global Powerbrands including Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Air Wick, Woolite and French's. Our Powerbrands represent 80% of net revenue.

 

RB is redefining the world of consumer health and hygiene. Our people and unique culture are at the heart of our success. We have a drive for achievement and a passion to outperform wherever we focus, including sustainability where we are targeting a 1/3 reduction in water impact, 1/3 reduction in carbon and 1/3 of net revenue from more sustainable products. We are proud to be Save the Children's largest global partner, with a new vision to radically reduce one of the world's largest killers of under 5s, diarrhoea.

 

For more information visit www.rb.com 

 

*RB is the trading name of the Reckitt Benckiser group of companies

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSDBLFFQLFFBBQ

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.